Published in Gastroenterology on February 01, 2004
TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis | NCT00222014
Tips Underdilatation in Patients With Cirrhosis | NCT03363412
Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt. J Hepatol (2007) 1.59
Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ (2006) 1.10
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Transjugular Intrahepatic Portosystemic Shunt (TIPS) versus Balloon-occluded Retrograde Transvenous Obliteration (BRTO) for the Management of Gastric Varices. Semin Intervent Radiol (2011) 0.96
Embolization with the Amplatzer Vascular Plug in TIPS patients. Cardiovasc Intervent Radiol (2007) 0.94
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol (2012) 0.93
Management of portal hypertension. Postgrad Med J (2004) 0.90
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. World J Gastroenterol (2014) 0.89
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol (2014) 0.88
Acute esophageal variceal bleeding: Current strategies and new perspectives. World J Hepatol (2010) 0.87
The difficult transjugular intrahepatic portosystemic shunt: alternative techniques and "tips" to successful shunt creation. Semin Intervent Radiol (2005) 0.87
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Long-term follow-up of TIPS created with expanded poly-tetrafluoroethylene covered stents. Dig Dis Sci (2013) 0.85
Should stent-grafts replace bare stents for primary transjugular intrahepatic portosystemic shunts? Semin Intervent Radiol (2005) 0.85
Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol (2011) 0.85
Endoscopic treatment of esophageal varices in patients with liver cirrhosis. World J Gastroenterol (2014) 0.84
Transjugular intrahepatic portosystemic shunt. Clin Liver Dis (2014) 0.84
Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center. World J Gastroenterol (2013) 0.83
Parallel shunt for the treatment of transjugular intrahepatic portosystemic shunt dysfunction. Korean J Radiol (2013) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol (2005) 0.80
Child-Na score: a predictive model for survival in cirrhotic patients with symptomatic portal hypertension treated with TIPS. PLoS One (2013) 0.80
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract (2013) 0.79
Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2014) 0.79
Management of gastric varices unsuccessfully treated by balloon-occluded retrograde transvenous obliteration: long-term follow-up and outcomes. ScientificWorldJournal (2013) 0.78
Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World J Gastroenterol (2012) 0.77
Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts. World J Gastroenterol (2015) 0.77
Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract (2014) 0.77
Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt. World J Gastroenterol (2014) 0.77
Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis. Dig Dis Sci (2012) 0.77
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open (2013) 0.76
Liver failure after an uncovered TIPS procedure associated with hepatic infarction. World J Hepatol (2010) 0.76
Hospitalization for variceal hemorrhage in an era with more prevalent cirrhosis. World J Gastroenterol (2014) 0.75
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Role of endoscopy in management of gastrointestinal complications of portal hypertension. World J Gastrointest Endosc (2015) 0.75
A Case of Isolated Duodenal Varices Secondary to Chronic Pancreatitis with Review of Literature. Gastroenterology Res (2010) 0.75
Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. World J Gastroenterol (2010) 0.75
Recurrent thrombotic occlusion of a transjugular intrahepatic portosystemic stent-shunt due to activated protein C resistance. World J Gastroenterol (2005) 0.75
Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Therap Adv Gastroenterol (2016) 0.75
Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt. World J Hepatol (2016) 0.75
Can an incomplete stent expansion modulate the effects of TIPS? J Gastroenterol (2010) 0.75
Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75
Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver (2016) 0.75
Construction of Transjugular Intrahepatic Portosystemic Shunt: Bare Metal Stent/Stent-graft Combination versus Single Stent-graft, a Prospective Randomized Controlled Study with Long-term Patency and Clinical Analysis. Chin Med J (Engl) (2016) 0.75
Transjugular intrahepatic portosystemic shunt versus surgical shunting in the management of portal hypertension. Chin Med J (Engl) (2015) 0.75
EVS vs TIPS shunt for gastric variceal bleeding in patients with cirrhosis: A meta-analysis. World J Gastrointest Pharmacol Ther (2014) 0.75
Comparison of Transjugular Intrahepatic Portosystemic Shunt with Covered Stent and Balloon-Occluded Retrograde Transvenous Obliteration in Managing Isolated Gastric Varices. Korean J Radiol (2017) 0.75
Outcomes of transjugular intrahepatic portosystemic shunts for ascites. Semin Intervent Radiol (2014) 0.75
Evaluation of Doppler-ultrasonography in the diagnosis of transjugular intrahepatic portosystemic shunt dysfunction: A prospective study. World J Hepatol (2017) 0.75
Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results. Eur Radiol (2016) 0.75
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol (2012) 4.62
Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol (2008) 4.12
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology (2011) 3.70
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation (2009) 2.78
Retrograde ascending aortic dissection during or after thoracic aortic stent graft placement: insight from the European registry on endovascular aortic repair complications. Circulation (2009) 2.74
Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv (2013) 2.69
Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol (2011) 2.61
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology (2006) 2.39
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology (2010) 2.39
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Impact of meteorological conditions on the occurrence of acute type A aortic dissections. Interact Cardiovasc Thorac Surg (2009) 2.34
Angiogenesis in liver disease. J Hepatol (2008) 2.31
TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology (2008) 2.25
Interdisciplinary expert consensus document on management of type B aortic dissection. J Am Coll Cardiol (2013) 2.24
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol (2012) 2.17
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology (2014) 2.12
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol (2006) 1.90
Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology (2013) 1.89
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int (2012) 1.83
Current management of portal hypertension. J Hepatol (2003) 1.81
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology (2005) 1.77
Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int (2010) 1.77
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int (2007) 1.66
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut (2011) 1.66
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Endovascular treatment of patients with types A and B thoracic aortic dissection using Relay thoracic stent-grafts: results from the RESTORE Patient Registry. J Endovasc Ther (2011) 1.58
Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol (2009) 1.57
Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol (2008) 1.56
Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology (2003) 1.54
Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2012) 1.53
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology (2010) 1.53
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. J Gastroenterol Hepatol (2012) 1.52
Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. J Clin Endocrinol Metab (2003) 1.50
Surgical exclusion of a symptomatic circumflex coronary to right atrium fistula. Interact Cardiovasc Thorac Surg (2007) 1.49
Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.48
Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int (2009) 1.48
Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int (2013) 1.46
Segmental liver ischemia after TIPS procedure using a new PTFE-covered stent. Hepatology (2002) 1.45
The management of portal hypertension: rational basis, available treatments and future options. J Hepatol (2008) 1.43
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology (2006) 1.42
Anticoagulation in cirrhosis: ready … set … wait! Hepatology (2013) 1.41
Developments and controversies in the management of oesophageal and gastric varices. Gut (2010) 1.40
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol (2010) 1.38
Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol (2010) 1.37
Gated blood pool SPECT: The estimation of right ventricular volume and function is algorithm dependent in a clinical setting. J Nucl Cardiol (2015) 1.36
Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol (2012) 1.34
Percutaneous embolization of iatrogenic arterial kidney injuries: safety, efficacy, and impact on blood pressure and renal function. J Vasc Interv Radiol (2011) 1.34
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 1.30
Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis (2006) 1.29
Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol (2004) 1.28
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology (2013) 1.23
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology (2007) 1.23
Age assessment by magnetic resonance imaging of the knee: a preliminary study. Forensic Sci Int (2011) 1.23
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol (2005) 1.18
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology (2004) 1.18
One-year outcomes following repair of thoracoabdominal aneurysms with the multilayer flow modulator: report from the STRATO trial. J Endovasc Ther (2014) 1.17